The IMID Forum

Professor Kevin Winthrop, Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, from Oregon Health and Science University, USA, as well as a CSF Steering Committee member. In this edition Professor Winthrop discusses his recent paper 'Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.'

Join Professor Philip Mease and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in December 2022. The first of our papers discusses the latest trial of a novel scoring system for inflammation and tissue damage, whilst the second paper compares adjunctive therapy usage in patients treated with IL-17A inhibitors.

Dr Rebecca Haberman from the Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, USA. In this edition Dr Haberman disucsses her recent paper ‘Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.’

Professor Roy Fleischmann, Clinical Professor of Medicine at the University of Texas Southwestern Medical Centre. In this addition Professor Fleischmann discusses his recent paper 'Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.'

Dr Claudia Salinas, Director Pharmacoepidemiology at Eli Lilly and Company, Indianapolis, USA. In this addition Dr Salinas discusses her recent paper 'Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease registries and Claims Databases.'

Join Prof Iain McInnes as he reviews two interesting papers. The first highlights one of the three systematic literature reviews carried out to inform the 2022 EULAR RA management recommendations task force with the available evidence published since 2019. The second paper in today’s podcast looks at the recommendations themselves, by Smolen, et al, and I’ll highlight what’s remained the same and what’s changed from the 2019 recommendations. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Professor Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications details the 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis. The second of today’s papers explores the efficacy and safety of bDMARDs in axSpA managment.

Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Prof Iain McInnes as he reviews two interesting papers. The first paper aimed to compare the risk of MACEs and VTEs for patients initiating a JAKinib (tofacitinib and baricitinib) and those initiating adalimumab (TNFi) among a large and comprehensive real-world population of patients with RA. Our second paper aimed to evaluate the efficacy and safety of FIL200 and FIL100 compared with placebo and ADA, all with background MTX, in patients with MTX-IR RA in subgroups of those with all four PPFs versus those with fewer than four PPFs. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Join Professor Iain McInnes and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in October 2022. Our first paper seeks to examine the efficacy and safety of ixekizumab in patients with PsA and PsO. Our second paper today will highlight the comparative efficacy of multiple treatments in PsA utilising new data within an NMA framework. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Discussing Rheumatology: October 2022 by The Immune-Mediated Inflammatory Disease Forum